Frustrated Boehringer breaks off German Trajenta price talks
This article was originally published in Scrip
Executive Summary
Boehringer Ingelheim is breaking off price negotiations for its DPP-4 inhibitor Trajenta (linagliptin) with the GKV, the German association of sickness funds, the firm has told Scrip. The move comes as the company's frustration mounts with the new early benefit assessments that all new drugs must undergo in Germany.